Wave Life Sciences Ltd. (WVE)
NASDAQ: WVE · Real-Time Price · USD
8.63
+0.53 (6.54%)
At close: Aug 1, 2025, 4:00 PM
8.50
-0.13 (-1.51%)
After-hours: Aug 1, 2025, 6:40 PM EDT

Company Description

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform.

The company’s RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.

It is developing WVE-006, an RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-N531, an exon skipping oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington’s disease (HD).

The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD.

Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.

Wave Life Sciences Ltd.
Wave Life Sciences logo
CountrySingapore
Founded2012
IPO DateNov 11, 2015
IndustryBiotechnology
SectorHealthcare
Employees288
CEOPaul B. Bolno

Contact Details

Address:
Marina One East Tower, 7 Straits View No.12-00
Singapore, 018936
Singapore
Phone65 6236 3388
Websitewavelifesciences.com

Stock Details

Ticker SymbolWVE
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001631574
CUSIP NumberY95308105
ISIN NumberSG9999014716
SIC Code2834

Key Executives

NamePosition
Dr. Paul B. Bolno M.B.A., M.D.President, Chief Executive Officer and Director
Dr. Gregory L. Verdine Ph.D.Founder and Director
Kyle B. Moran CFAChief Financial Officer and Principal Accounting Officer
Dr. Chandra Vargeese Ph.D.Chief Technology Officer
Dr. Christopher Francis Ph.D.Senior Vice President of Corporate Development and Head of Emerging Areas
Dr. Erik Ingelsson M.D., Ph.D.Chief Scientific Officer
Kate RauschHead of Investor Relations
Linda Rockett J.D.Senior Vice President and General Counsel
Daryn LewisSenior Vice President and Head of Human Resources
Dr. Sridhar Vaddeboina M.B.A., Ph.D.Senior Vice President of Chemistry, Manufacturing and Controls

Latest SEC Filings

DateTypeTitle
Jul 30, 202510-QQuarterly Report
Jul 30, 20258-KCurrent Report
Jun 23, 2025ARSFiling
Jun 23, 2025DEF 14AOther definitive proxy statements
Jun 13, 2025144Filing
May 12, 2025SCHEDULE 13G/AFiling
May 8, 202510-QQuarterly Report
May 8, 20258-KCurrent Report
Apr 29, 202510-K/A[Amend] Annual report
Mar 26, 20258-KCurrent Report